Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The correlation between chemotherapy combined with immunotherapy and the evolution of intestinal flora in non-small cell lung cancer

ABSTRACT: Interventions: Adenocarcinoma group:Nought;Squamous cell carcinoma group:Nought Primary outcome(s): Progression-free survival Study Design: Cohort study

DISEASE(S): Non-small Cell Lung Cancer

PROVIDER: 83345 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Correlation between immunotherapy and intestinal flora evolution in non-small cell lung cancer

Project description:Interventions: Control group:None;Bacillus group :Live bacillus licheniformis capsule Primary outcome(s): Overall survival Study Design: Parallel

| 34999 | ecrin-mdr-crc

Correlation between chemotherapy and intestinal flora evolution in non-small cell lung cancer

Project description:Interventions: Control group:None;Bacillus group :Live bacillus licheniformis capsule Primary outcome(s): Overall survival Study Design: Parallel

| 35000 | ecrin-mdr-crc

The correlation between immunotherapy combined with anti-angiogenesis therapy and the evolution of intestinal flora in small cell lung cancer

Project description:Interventions: Group A:None;Group B:Live Bacillus Licheniformis Capsule;Group C:Live Combined Bacillus Subtilis and Enterocoocus Faecium Enteric-coated Capsules;Group D:Triple Viable Capsules Dissolving at Intestines Primary outcome(s): Overall survival Study Design: Parallel

| 83358 | ecrin-mdr-crc

The correlation between chemotherapy combined with immunotherapy and the evolution of intestinal flora in small cell lung cancer

Project description:Interventions: A:Naught;B:Live Bacillus licheniformis capsule;C:Live Combined Bacillus Subtilis and Enterocoocus Faecium Enteric-coated Capsules;D:Triple Viable Capsules Dissolving at Intestines Primary outcome(s): Overall survival Study Design: Parallel

| 83346 | ecrin-mdr-crc

Correlation between immune monotherapy and the evolution of intestinal flora in patients with small cell lung cancer

| 83356 | ecrin-mdr-crc

Non-small cell lung cancer global proteomics

Project description:We present data of global proteomes for non-small cell lung cancer for squamous cell and adenocarcinoma, and for normal adjacent tissue.

2024-12-17 | PXD054390 | Pride

Non Small Cell Lung Cancer

Project description:This series contain 36 samples obtained from human lung tissue and includes the following: 7 Adenocarcinoma samples. 16 Squamous cell carcinoma samples. 1 AdenoSquamous sample. 2 Renal Metastasis. 1 Colon metastasis. 7 normal lung tissue adjacent to the tumors. 2 commercial normal lung RNA. Keywords = Lung Keywords = Non Small Cell Lung Cancer Keywords = Adenocarcinoma Keywords = Squamous Cell Carcinoma Keywords = Normal Lung. Keywords: other

2005-07-20 | GSE1987 | GEO

Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora

Project description:This study collects stool, blood, and tumor tissue samples from patients with locally advanced esophageal cancer after receiving Sintilimab and chemotherapy to explore the efficacy and intestinal microbes of chemotherapy combined with neoadjuvant immunotherapy for locally advanced operable thoracic esophageal squamous cell carcinoma The main purpose is the relationship between its metabolites, and it will also explore the changes of intestinal flora diversity and metabolites before and after esophageal squamous cell carcinoma chemotherapy combined with immune neoadjuvant therapy

| 2401591 | ecrin-mdr-crc

[Advances of the Correlation between Driver Gene Status and Immunotherapy ?in Non-small Cell Lung Cancer].

Project description:In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of the unselected patients can benefit from the therapy, and there is a possibility of hyperprogression (HP). Therefore, how to select the dominant population is crucial. Although many studies have emphasized the importance of PD-L1 and tumor mutation burden (TMB) and other indicators to guide immunotherapy, current PD-L1 expression level and mutation load cannot be used as a decisive and excluded predictive marker based on various obstacles. With the deepening of research, we found that there is a close relationship between lung cancer-driver gene mutation and aberrant activation of PD-1/PD-L1 signal pathways, and the correlation between gene mutation and immunotherapy efficacy has broad research value. This article will revolve around the above issues.?.

| S-EPMC6500499 | biostudies-literature

Transcription profiling of human small cell lung cancer

Project description:This series contain 36 samples obtained from human lung tissue and includes the following:; 7 Adenocarcinoma samples. 16 Squamous cell carcinoma samples. 1 AdenoSquamous sample. 2 Renal Metastasis. 1 Colon metastasis. 7 normal lung tissue adjacent to the tumors. 2 commercial normal lung RNA.

2008-06-11 | E-GEOD-1987 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data